News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

GlaxoSmithKline (GSK)'s Contract Manufacturing Delays Cause Shortage of Restless Leg Treatment


4/18/2013 8:33:00 AM

The FDA announced a shortage of Horizant (gabapentin enacarbil; GlaxoSmithKline) 600mg extended-release tablets. Horizant is a prodrug of gabapentin that is indicated for postherpetic neuralgia and for moderate-to-severe primary restless legs syndrome in adults. GlaxoSmithKline is currently experiencing a backorder situation. XenoPort will assume manufacturing and commercialization of Horizant from May 1, 2013. XenoPort anticipates the Horizant shortage to extend into June 2013.


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES